This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Various				
Sepsis; liver cancer; colorectal cancer	Endothelial PAS domain protein 1 (EPAS1; HIF2A)	<i>In vitro</i> and mouse studies suggest that HIF2A inhibition could help treat sepsis, hepatocellular carcinoma (HCC) and colon cancer. In a mouse model of lipopolysaccharide (LPS)-induced sepsis, <i>Hif2a</i> knockout in bone marrow cells led to lower serum levels of proinflammatory cytokines and greater resistance to hypothermia than <i>Hif2a</i> expression. In mouse models of HCC and colitis-associated colorectal cancer, <i>Hif2a</i> knockout decreased tumor growth compared with <i>Hif2a</i> expression. Ongoing work includes testing small molecule HIF2A inhibitors in the mouse models of sepsis, HCC and colitis-associated colorectal cancer.	Unpatented; available for licensing	Imtiyaz, H.Z. <i>et al. J. Clin. Invest.</i> ; published online July 19, 2010; doi:10.1172/JCI39506 Contact: M. Celeste Simon, University of Pennsylvania, Philadelphia, Pa. e-mail: celeste2@mail.med.upenn.edu
SciBX 3(29); doi:10.1038/scibx.2010.903 Published online July 29, 2010				